Sobi: A Year of Remarkable Growth
Swedish Orphan Biovitrum AB (publ) (Sobi) has recently shared exciting news regarding its performance for the fourth quarter and the entire 2025 fiscal year. The year was marked by significant advancements and a robust financial outlook, showcasing Sobi's commitment to innovation in the biopharma industry.
Fourth Quarter Highlights
The fourth quarter of 2025 saw total revenue rise by 5%, amounting to SEK 7,821 million, with an impressive growth rate of 16% when adjusted for constant exchange rates (CER). This strong performance was largely driven by the haematology segment, which alone recorded a remarkable 25% increase at CER, reaching SEK 5,143 million.
Leading Products Fuel Growth
A significant contributor to this growth came from the sales of Altuvoct, which generated SEK 1,023 million, and Doptelet, which contributed SEK 1,508 million. Although sales of Vonjo decreased to SEK 327 million, the overall performance in haematology remained exceptional.
In the immunology segment, revenue saw modest growth of 2% at CER, totaling SEK 2,337 million. This increase was primarily driven by robust sales of Gamifant and Kineret, which brought in SEK 763 million and SEK 741 million respectively. However, there was a decline in Beyfortus royalties, contributing SEK 849 million compared to previous figures.
Full Year Financial Overview
For the full year, Sobi reported total revenue growth of 8%, reaching SEK 28,238 million. This included a 23% increase in haematology and a 1% uptick in the immunology sector, highlighting the company's steady expansion in key therapeutic areas.
Profitability Metrics
The company achieved a commendable adjusted EBITA margin of 40%, reflecting strong operational efficiency and profitable growth. However, it was decided that no dividend would be paid for the financial year 2025, as the board of directors seeks to reinvest earnings into further growth initiatives.
Looking Ahead: Outlook for 2026
As we move into 2026, Sobi anticipates revenue growth in the low double-digit percentage range at CER. This positive outlook is supported by the company's strategic initiatives aimed at enhancing its product pipeline and driving sales across both haematology and immunology sectors.
Financial Expectations
The adjusted EBITA margin for the upcoming year is expected to settle in the mid-30s percentage of revenue, hinting at consistent health for Sobi’s financial positioning.
Engagement with Stakeholders
To discuss these results in further detail, Sobi invites investors, analysts, and media representatives to a conference call scheduled shortly after this report. The call will include a presentation along with a Q&A session to address any inquiries from stakeholders.
Accessing the Presentation
Participants will have the opportunity to join the conference call and view live updates through Sobi’s official communication channels, which will also provide presentations and additional resources following the call.
Sobi's Commitment to Rare Diseases
Sobi is a dedicated biopharma company focused on enhancing the quality of life for individuals affected by rare diseases. With a diverse team of approximately 1,900 employees spread across several regions, the company prides itself on its innovative solutions and commitment to patient well-being.
As Sobi continues to pave the way in the biopharma landscape, its aspiration remains to develop breakthrough treatments that significantly improve everyday life for those impacted by challenging health conditions. The journey of Sobi is not only about financial growth but also about the lives it changes through its dedicated treatment approaches.
Frequently Asked Questions
What were Sobi's total revenues for the fourth quarter of 2025?
Total revenue for the fourth quarter of 2025 was SEK 7,821 million.
How did the haematology segment perform in 2025?
The haematology segment saw a 25% growth at constant exchange rates, generating SEK 5,143 million in revenue.
What is Sobi's outlook for 2026?
Sobi anticipates revenue growth in the low double-digit percentage range for 2026.
What decisions were made regarding dividends for 2025?
The board proposed that no dividend be paid for the financial year 2025.
How many employees does Sobi have globally?
Sobi employs approximately 1,900 individuals across its global operations.
